Revenue Update on Baxter International Inc(NYSE:BAX)

Baxter International Inc(NYSE:BAX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 26, 2016. Company reported revenue of $2.58B. Analysts estimated a revenue of $2.51B. Earnings per share were $0.46. Analysts had estimated an EPS of $0.39.

In a different note, Evercore ISI Group said it Initiates Coverage on Baxter International Inc, according to a research note issued on May 4, 2016. The shares have been rated ‘Buy’ by the firm.

Baxter International Inc (BAX) shares turned negative on Fridays trading session with the shares closing down -0.2 points or -0.41% at a volume of 54,89,155. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $48.34. The peak price level was also seen at $48.34 while the days lowest was $47.82. Finally the shares closed at $48.02. The 52-week high of the shares is $48.5 while the 52-week low is $32.18. According to the latest information available, the market cap of the company is $26,520 M.

Baxter International Inc has also declared a cash dividend of $0.1300 on Jul 19, 2016. The shares will quote ex-dividend on Aug 31, 2016 and the record date has been fixed on Sep 2, 2016. The dividend payable date has been fixed on Oct 3, 2016.

Several Insider Transactions has been reported to the SEC. On May 24, 2016, Jose E Almeida (CEO) purchased 11,691 shares at $42.75 per share price.Also, On May 4, 2016, John D Forsyth (director) sold 1,887 shares at $44.38 per share price.On Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price, according to the Form-4 filing with the securities and exchange commission.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.